ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ARDX vs HELP // PIOTROSKI F-SCORE QUALITY

Ardelyx Inc. (NASDAQ) VS. Helus Pharma Inc. (NASDAQ) • 15-METRIC TALLY: ARDX 0 — HELP 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARDX VS. HELP) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ARDX HELP SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 90.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -32.70% — — TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -5.69% — — TIE /fcf-yield <GO>
Operating Margin -10.10% — — TIE /operating-margins <GO>
Net Profit Margin -15.20% — — TIE /net-margins <GO>
Revenue Growth (YoY) 22.10% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality ACTIVE 4/9 — — TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 37.3 44.7 -7.41 HELP /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $772.5M $782.5M -$10.0M HELP /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ARDX REV HELP REV ARDX GROSS % HELP GROSS % ARDX FCF HELP FCF
FY 2025 $407.3M — 90.3% — -$44.0M —
FY 2024 $333.6M — 84.8% — -$45.8M —
FY 2023 $124.5M — — — -$89.7M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARDX // BETA —
HELP // BETA —